Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma
This study has been terminated.
Sponsor:
University of Pennsylvania
Collaborators:
Bristol-Myers Squibb
Roche Pharma AG
Information provided by:
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00353457
First received: July 14, 2006
Last updated: September 29, 2010
Last verified: September 2010
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Received Date ICMJE | July 14, 2006 | ||||||||
Last Updated Date | September 29, 2010 | ||||||||
Start Date ICMJE | February 2006 | ||||||||
Estimated Primary Completion Date | February 2010 (final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
Pathologic complete response [ Time Frame: After neoadjuvant treatment ] [ Designated as safety issue: No ] | ||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||
Change History | Complete list of historical versions of study NCT00353457 on ClinicalTrials.gov Archive Site | ||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||
Current Other Outcome Measures ICMJE | |||||||||
Original Other Outcome Measures ICMJE | |||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma | ||||||||
Official Title ICMJE | Phase II Study of Capecitabine, Oxaliplatin and Cetuximab Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma | ||||||||
Brief Summary | This is a phase II study of induction chemotherapy (capecitabine, oxaliplatin and cetuximab (erbitux)) followed by capecitabine, oxaliplatin, cetuximab and radiotherapy followed by surgery followed by adjuvant capecitabine, oxaliplatin and cetuximab for locally advanced resectable rectal cancer. |
||||||||
Detailed Description | |||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase | Phase 2 | ||||||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
||||||||
Condition ICMJE | Rectal Cancer | ||||||||
Intervention ICMJE |
|
||||||||
Study Arm (s) | |||||||||
Publications * | |||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Terminated | ||||||||
Estimated Enrollment ICMJE | 40 | ||||||||
Completion Date | |||||||||
Estimated Primary Completion Date | February 2010 (final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Gender | Both | ||||||||
Ages | 18 Years and older | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||
Location Countries ICMJE | |||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT00353457 | ||||||||
Other Study ID Numbers ICMJE | 803437, UPCC 09204 | ||||||||
Has Data Monitoring Committee | Yes | ||||||||
Responsible Party | Daniel Haller, MD, University of Pennsylvania | ||||||||
Study Sponsor ICMJE | University of Pennsylvania | ||||||||
Collaborators ICMJE |
|
||||||||
Investigators ICMJE |
|
||||||||
Information Provided By | University of Pennsylvania | ||||||||
Verification Date | September 2010 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |